Design and characterization of an HIV-1 Tat mutant: Inactivation of viral and cellular functions but not antigenicity

Vaccine

Volumn 25, Issue 32, 2007, Pages 6047-6060

  Mayol, Katia ^a   Munier, Séverine ^a   Beck, Alain ^b   Verrier, Bernard ^a   Guillon, Christophe ^a  

^a BIOMÉRIEUX   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antigenicity; Detoxification; HIV 1 Tat

Indexed keywords

FREUND ADJUVANT; GAG PROTEIN; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUTANT PROTEIN; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EMBRYO; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSACTIVATION; VIRUS TRANSCRIPTION; WILD TYPE;

AIDS VACCINES; CELL LINE; GENE EXPRESSION REGULATION; GENE PRODUCTS, TAT; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV ANTIGENS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MUTATION;

EID: 34447521820     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.048     Document Type: Article

References (67)

1. Jeang K.T., Xiao H., and Rich E.A. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem 274 41 (1999) 28837-28840
2. Yang M. Discoveries of Tat-TAR interaction inhibitors for HIV-1. Curr Drug Targets Infect Disord 5 4 (2005) 433-444
3. Fujinaga K., Irwin D., Huang Y., Taube R., Kurosu T., and Peterlin B.M. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol Cell Biol 24 2 (2004) 787-795
4. Demirhan I., Chandra A., Mueller F., Mueller H., Biberfeld P., Hasselmayer O., et al. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma. J Hum Virol 3 3 (2000) 137-143
5. van Baalen C.A., Pontesilli O., Huisman R.C., Geretti A.M., Klein M.R., de Wolf F., et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 78 Pt 8 (1997) 1913-1918
6. Stittelaar K.J., Gruters R.A., Schutten M., van Baalen C.A., van Amerongen G., Cranage M., et al. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 20 23/24 (2002) 2921-2927
7. Ferrantelli F., Cafaro A., and Ensoli B. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr Opin Biotechnol 15 6 (2004) 543-556
8. Mischiati C., Pironi F., Milani D., Giacca M., Mirandola P., Capitani S., et al. Extracellular HIV-1 Tat protein differentially activates the JNK and ERK/MAPK pathways in CD4 T cells. Aids 13 13 (1999) 1637-1645
9. Rusnati M., and Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. Angiogenesis 5 3 (2002) 141-151
10. Li W., Galey D., Mattson M.P., and Nath A. Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res 8 1/2 (2005) 119-134
11. Ehret A., Li-Weber M., Frank R., and Krammer P.H. The effect of HIV-1 regulatory proteins on cellular genes: derepression of the IL-2 promoter by Tat. Eur J Immunol 31 6 (2001) 1790-1799
12. Ott M., Lovett J.L., Mueller L., and Verdin E. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kappaB factors. J Immunol 160 6 (1998) 2872-2880
13. Howcroft T.K., Strebel K., Martin M.A., and Singer D.S. Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science 260 5112 (1993) 1320-1322
14. Okamoto H., Asamitsu K., Nishimura H., Kamatani N., and Okamoto T. Reciprocal modulation of transcriptional activities between HIV-1 Tat and MHC class II transactivator CIITA. Biochem Biophys Res Commun 279 2 (2000) 494-499
15. Li J.C., Lee D.C., Cheung B.K., and Lau A.S. Mechanisms for HIV Tat upregulation of IL-10 and other cytokine expression: kinase signaling and PKR-mediated immune response. FEBS Lett 579 14 (2005) 3055-3062
16. Vendeville A., Rayne F., Bonhoure A., Bettache N., Montcourrier P., and Beaumelle B. HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol Biol Cell 15 5 (2004) 2347-2360
17. Huigen M.C., Kamp W., and Nottet H.S. Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection. Eur J Clin Invest 34 1 (2004) 57-66
18. Corallini A., Altavilla G., Pozzi L., Bignozzi F., Negrini M., Rimessi P., et al. Systemic expression of HIV-1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res 53 22 (1993) 5569-5575
19. Gavriil E.S., Cooney R., and Weeks B.S. Tat mediates apoptosis in vivo in the rat central nervous system. Biochem Biophys Res Commun 267 1 (2000) 252-256
20. Cohen S.S., Li C., Ding L., Cao Y., Pardee A.B., Shevach E.M., et al. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc Natl Acad Sci USA 96 19 (1999) 10842-10847
21. Agwale S.M., Shata M.T., Reitz Jr. M.S., Kalyanaraman V.S., Gallo R.C., Popovic M., et al. A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice. Proc Natl Acad Sci USA 99 15 (2002) 10037-10041
22. Prakash O., Teng S., Ali M., Zhu X., Coleman R., Dabdoub R.A., et al. The human immunodeficiency virus type 1 Tat protein potentiates zidovudine-induced cellular toxicity in transgenic mice. Arch Biochem Biophys 343 2 (1997) 173-180
23. Caputo A., Gavioli R., and Ensoli B. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res 2 4 (2004) 357-376
24. Ensoli B., and Cafaro A. HIV-1 Tat vaccines. Virus Res 82 1-2 (2002) 91-101
25. Silvera P., Richardson M.W., Greenhouse J., Yalley-Ogunro J., Shaw N., Mirchandani J., et al. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol 76 8 (2002) 3800-3809
26. Le Buanec H., and Bizzini B. Procedures for preparing biologically inactive, but immunogenic HIV-1 Tat protein (Tat toxoid) for human use. Biomed Pharmacother 54 1 (2000) 41-44
27. Zagury J.F., Sill A., Blattner W., Lachgar A., Le Buanec H., Richardson M., et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1 4 (1998) 282-292
28. Betti M., Voltan R., Marchisio M., Mantovani I., Boarini C., Nappi F., et al. Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. Vaccine 19 25/26 (2001) 3408-3419
29. Bartz S.R., and Emerman M. Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/caspase-8. J Virol 73 3 (1999) 1956-1963
30. Tosi G., De Lerma Barbaro A., D'Agostino A., Valle M.T., Megiovanni A.M., Manca F., et al. HIV-1 Tat mutants in the cysteine-rich region downregulate HLA class II expression in T lymphocytic and macrophage cell lines. Eur J Immunol 30 1 (2000) 19-28
31. Felber B.K., and Pavlakis G.N. A quantitative bioassay for HIV-1 based on trans-activation. Science 239 4836 (1988) 184-187
32. Sadaie M.R., and Hager G.L. Induction of developmentally programmed cell death and activation of HIV by sodium butyrate. Virology 202 1 (1994) 513-518
33. Weiss A., Wiskocil R.L., and Stobo J.D. The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level. J Immunol 133 1 (1984) 123-128
34. Groenink M., Andeweg A.C., Fouchier R.A., Broersen S., van der Jagt R.C., Schuitemaker H., et al. Phenotype-associated env gene variation among eight related human immunodeficiency virus type 1 clones: evidence for in vivo recombination and determinants of cytotropism outside the V3 domain. J Virol 66 10 (1992) 6175-6180
35. Guillon C., Bedin F., Fouchier R.A., Schuitemaker H., and Gruters R.A. Completion of nucleotide sequences of non-syncytium-inducing and syncytium-inducing HIV type 1 variants isolated from the same patient. AIDS Res Hum Retroviruses 11 12 (1995) 1537-1541
36. Higuchi R. Recombinant PCR. In: Innis M., Gelfand D., Sninsky J., and White T. (Eds). PCR protocols: a guide to methods and applications (1990), Academic Press, San Diego 177-183
37. Sambrook J., Fritsch E., and Maniatis T. Molecular cloning. A laboratory manual (1989), Cold Spring Harbor Laboratory Press, New York
38. Guillon C., Schutten M., Boers P.H., Gruters R.A., and Osterhaus A.D. Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction. J Virol 76 6 (2002) 2827-2834
39. Foucault M, Guillon C, Mayol K, Menduni R, Bussat M, Klinguer-Hamour C, et al. Structural study of chemically synthesized Tat proteins from a HIV-1 primary isolate: evidence that Tat is a natively unfolded protein in solution. Proteins 2007; submitted for publication.
40. Baldari C.T., Macchia G., Massone A., and Telford J.L. p21ras contributes to HIV-1 activation in T-cells. FEBS Lett 304 2/3 (1992) 261-264
41. Ataman-Onal Y., Munier S., Ganee A., Terrat C., Durand P.Y., Battail N., et al. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J Control Release 112 2 (2006) 175-185
42. Cheynet V., Verrier B., and Mallet F. Overexpression of HIV-1 proteins in Escherichia coli by a modified expression vector and their one-step purification. Protein Exp Purif 4 5 (1993) 367-372
43. Guillon C., Stankovic K., Ataman-Onal Y., Biron F., and Verrier B. Evidence for CTL-mediated selection of Tat and Rev mutants after the onset of the asymptomatic period during HIV type 1 infection. AIDS Res Hum Retroviruses 22 12 (2006) 1283-1292
44. Partidos C.D., Moreau E., Chaloin O., Tunis M., Briand J.P., Desgranges C., et al. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity. Eur J Immunol 34 12 (2004) 3723-3731
45. Bahner I., Zhou C., Yu X.J., Hao Q.L., Guatelli J.C., and Kohn D.B. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes. J Virol 67 6 (1993) 3199-3207
46. Kuppuswamy M., Subramanian T., Srinivasan A., and Chinnadurai G. Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res 17 9 (1989) 3551-3561
47. Weissman J.D., Brown J.A., Howcroft T.K., Hwang J., Chawla A., Roche P.A., et al. HIV-1 tat binds TAFII250 and represses TAFII250-dependent transcription of major histocompatibility class I genes. Proc Natl Acad Sci USA 95 20 (1998) 11601-11606
48. Smith S.M., Pentlicky S., Klase Z., Singh M., Neuveut C., Lu C.Y., et al. An in vivo replication-important function in the second coding exon of Tat is constrained against mutation despite cytotoxic T lymphocyte selection. J Biol Chem 278 45 (2003) 44816-44825
49. Neuveut C., Scoggins R.M., Camerini D., Markham R.B., and Jeang K.T. Requirement for the second coding exon of Tat in the optimal replication of macrophage-tropic HIV-1. J Biomed Sci 10 6 Pt 1 (2003) 651-660
50. Blazquez M.V., Macho A., Ortiz C., Lucena C., Lopez-Cabrera M., Sanchez-Madrid F., et al. Extracellular HIV type 1 Tat protein induces CD69 expression through NF-kappaB activation: possible correlation with cell surface Tat-binding proteins. AIDS Res Hum Retroviruses 15 13 (1999) 1209-1218
51. Gonzalez E., Punzon C., Gonzalez M., and Fresno M. HIV-1 Tat inhibits IL-2 gene transcription through qualitative and quantitative alterations of the cooperative Rel/AP1 complex bound to the CD28RE/AP1 composite element of the IL-2 promoter. J Immunol 166 7 (2001) 4560-4569
52. Marecki J.C., Cota-Gomez A., Vaitaitis G.M., Honda J.R., Porntadavity S., St Clair D.K., et al. HIV-1 Tat regulates the SOD2 basal promoter by altering Sp1/Sp3 binding activity. Free Radic Biol Med 37 6 (2004) 869-880
53. Shojania S., and O'Neil J.D. HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy. J Biol Chem 281 13 (2006) 8347-8356
54. Howcroft T.K., Raval A., Weissman J.D., Gegonne A., and Singer D.S. Distinct transcriptional pathways regulate basal and activated major histocompatibility complex class I expression. Mol Cell Biol 23 10 (2003) 3377-3391
55. Chiu Y.L., Cao H., Jacque J.M., Stevenson M., and Rana T.M. Inhibition of human immunodeficiency virus type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J Virol 78 5 (2004) 2517-2529
56. Hauber J., Malim M.H., and Cullen B.R. Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. J Virol 63 3 (1989) 1181-1187
57. Kumar P.P., Purbey P.K., Ravi D.S., Mitra D., and Galande S. Displacement of SATB1-bound histone deacetylase 1 corepressor by the human immunodeficiency virus type 1 transactivator induces expression of interleukin-2 and its receptor in T cells. Mol Cell Biol 25 5 (2005) 1620-1633
58. Puri R.K., Leland P., and Aggarwal B.B. Constitutive expression of human immunodeficiency virus type 1 tat gene inhibits interleukin 2 and interleukin 2 receptor expression in a human CD4 + T lymphoid (H9) cell line. AIDS Res Hum Retroviruses 11 1 (1995) 31-40
59. Yamato M., Nagahama K., Kotani T., Kato S., and Takeuchi K. Biphasic effect of prostaglandin E2 in a rat model of esophagitis mediated by EP1 receptors: relation to pepsin secretion. Digestion 72 2-3 (2005) 109-118
60. Woods D., Parry D., Cherwinski H., Bosch E., Lees E., and McMahon M. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17 9 (1997) 5598-5611
61. Lechel A., Satyanarayana A., Ju Z., Plentz R.R., Schaetzlein S., Rudolph C., et al. The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo. EMBO Rep 6 3 (2005) 275-281
62. De A.K., Miller-Graziano C.L., Calvano S.E., Laudanski K., Lowry S.F., Moldawer L.L., et al. Selective activation of peripheral blood T cell subsets by endotoxin infusion in healthy human subjects corresponds to differential chemokine activation. J Immunol 175 9 (2005) 6155-6162
63. Tulic M.K., Manoukian J.J., Eidelman D.H., and Hamid Q. T-cell proliferation induced by local application of LPS in the nasal mucosa of nonatopic children. J Allergy Clin Immunol 110 5 (2002) 771-776
64. Clerici M., Hakim F.T., Venzon D.J., Blatt S., Hendrix C.W., Wynn T.A., et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 91 3 (1993) 759-765
65. Kapogiannis B.G., Henderson S.L., Nigam P., Sharma S., Chennareddi L., Herndon J.G., et al. Defective IL-2 production by HIV-1-specific CD4 and CD8 T cells in an adolescent/young adult cohort. AIDS Res Hum Retroviruses 22 3 (2006) 272-282
66. Purvis S.F., Georges D.L., Williams T.M., and Lederman M.M. Suppression of interleukin-2 and interleukin-2 receptor expression in Jurkat cells stably expressing the human immunodeficiency virus Tat protein. Cell Immunol 144 1 (1992) 32-42
67. Pimentel-Muinos F.X., Munoz-Fernandez M.A., and Fresno M. Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines. J Immunol 152 12 (1994) 5714-5722